Comparative Pharmacology
Head-to-head clinical analysis: MAXALT MLT versus NEXCEDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAXALT MLT versus NEXCEDE.
MAXALT-MLT vs NEXCEDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective 5-HT1B/1D receptor agonist; causes vasoconstriction of intracranial arteries and inhibits trigeminal nerve activation.
NEXCEDE is a combination of omeprazole (proton pump inhibitor) and naproxen (nonsteroidal anti-inflammatory drug). Omeprazole irreversibly inhibits the gastric H+/K+-ATPase pump, reducing gastric acid secretion. Naproxen inhibits cyclooxygenase (COX)-1 and COX-2, decreasing prostaglandin synthesis, which reduces inflammation, pain, and fever.
10 mg orally as a single dose; maximum 30 mg in 24 hours. Administer at onset of migraine; do not use for prophylaxis.
50-100 mg orally twice daily, with or without food. Maximum 200 mg/day.
None Documented
None Documented
Terminal elimination half-life of approximately 2-3 hours; clinical context: short half-life supports acute migraine treatment with rapid offset.
Terminal elimination half-life is approximately 8 hours in patients with normal renal function. This supports twice-daily dosing. In patients with renal impairment (CrCl <30 mL/min), half-life may extend to 15-20 hours, requiring dose adjustment.
Primarily hepatic metabolism; ~14% excreted unchanged in urine, ~76% as metabolites in feces via bile, total renal excretion of parent and metabolites ~40%.
Primarily renal excretion of unchanged drug (approximately 60% of the dose via glomerular filtration and tubular secretion). Biliary/fecal excretion accounts for about 30% of the dose. Less than 10% is metabolized.
Category C
Category C
Antimigraine Agent
Antimigraine Agent